Human Genome Epidemiology Literature Finder
Records 1 - 10 (of 10 Records) |
Query Trace: Gastrointestinal Neoplasms and DPYD[original query] |
---|
(13)C-uracil breath test to predict 5-fluorouracil toxicity in gastrointestinal cancer patients. Cancer chemotherapy and pharmacology 2013 Dec 72 (6): 1273-82. Cunha-Junior Geraldo Felício, De Marco Luiz, Bastos-Rodrigues Luciana, Bolina Marina Borges, Martins Flavia Linhares, Pianetti Gerson Antonio, Cesar Isabela Costa, Coelho Luiz Gonza |
The TYMS-TSER polymorphism is associated with toxicity of low-dose capecitabine in patients with advanced gastrointestinal cancer. Anti-cancer drugs 2016 11 27 (10): 1044-9. Romiti Adriana, Roberto Michela, D'Antonio Chiara, Onesti Concetta E, Barucca Viola, Milano Annalisa, Gentile Giovanna, Lionetto Luana, Medda Emanuela, Mazzuca Federica, Botticelli Andrea, Falcone Rosa, Simmaco Maurizio, Marchetti Pao |
Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine. European journal of clinical pharmacology 2016 Nov . Roberto Michela, Romiti Adriana, Botticelli Andrea, Mazzuca Federica, Lionetto Luana, Gentile Giovanna, Paris Ida, Falcone Rosa, Bassanelli Maria, Di Pietro Francesca Romana, Onesti Concetta Elisa, Anselmi Elisabetta, Macrini Serena, Simmaco Maurizio, Marchetti Pao |
5-Fluorouracil degradation rate could predict toxicity in stages II-III colorectal cancer patients undergoing adjuvant FOLFOX. Anti-cancer drugs 2016 Nov . Onesti Concetta E, Botticelli Andrea, La Torre Marco, Borro Marina, Gentile Giovanna, Romiti Adriana, Lionetto Luana, Petremolo Antonella, Occhipinti Mario, Roberto Michela, Falcone Rosa, Simmaco Maurizio, Marchetti Paolo, Mazzuca Federi |
Endogenous plasma and salivary uracil to dihydrouracil ratios and DPYD genotyping as predictors of severe fluoropyrimidine toxicity in patients with gastrointestinal malignancies. Clinical biochemistry 2016 Jul . Galarza Andrés Fernando Andrade, Linden Rafael, Antunes Marina Venzon, Hahn Roberta Zilles, Raymundo Suziane, da Silva Anne Caroline Cezimbra, Staggemeier Rodrigo, Spilki Fernando Rosado, Schwartsmann Gilber |
Fluoropyrimidine-Associated Toxicity in Two Gastrointestinal Cancer Patients: Potential Role of Common DPYD Polymorphisms. Chemotherapy 2017 Jun 62 (5): 323-326. Falvella Felicia Stefania, Luoni Marco, Cheli Stefania, Fava Sergio, Cergnul Massimilia |
Frequency and clinical relevance of DPYD genetic variants in gastrointestinal cancer patients. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 2022 4 45 (7): 5-10. Riera Pau, Riba Mireia, Bernal Sara, Virgili Anna C, Páez David, Moreno M Este |
Survey of US Medical Oncologists' Practices and Beliefs Regarding DPYD Testing Before Fluoropyrimidine Chemotherapy. JCO oncology practice 2022 3 18 (6): e958-e965. Koo Kyoin, Pasternak Amy L, Henry N Lynn, Sahai Vaibhav, Hertz Daniel |
Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre. BMC cancer 2023 4 23 (1): 380. David K Lau, Caroline Fong, Faten Arouri, Lillian Cortez, Hannah Katifi, Reyes Gonzalez-Exposito, Muhammad Bilal Razzaq, Su Li, Aislinn Macklin-Doherty, Monica Arenas Hernandez, Michael Hubank, Charlotte Fribbens, David Watkins, Sheela Rao, Ian Chau, David Cunningham, Naureen Starli |
Implementation and clinical benefit of DPYD genotyping in a Danish cancer population. ESMO open 2023 2 8 (1): 100782. Paulsen N H, Pfeiffer P, Ewertz M, Fruekilde P B N, Feddersen S, Holm H S, Bergmann T K, Qvortrup C, Damkier |
- Page last reviewed:Feb 1, 2024
- Page last updated:May 06, 2024
- Content source: